INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...

As an alternative to antibodies, proof-of-concept of the clinical efficacy of new protein scaffolds with different pharmacological properties and less expensive manufacturing processes might also ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Pharmaceuticals announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs) Findings in HIV highlight AMV technology's versatility, robust ...

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

A new study in the peer-reviewed journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick ...

The report also provides you with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular ...